Vergent Bioscience
Latest round
- Series B
Last raised
- Aug 2022
Total raised
- $30M
Investors
- 7
About Vergent Bioscience
Vergent Bioscience develops advanced tumor-targeted fluorescent imaging agents, enhancing tumor visibility during surgeries.Vergent Bioscience, Inc. is focused on creating advanced imaging solutions for surgical applications, particularly in oncology.Vergent Bioscience specializes in the development of advanced tumor-targeted fluorescent imaging agents, with its lead product, abenacianine for injection (VGT-309). This imaging agent enhances tumor visibility during minimally invasive surgeries, particularly for lung cancer, and has potential applications across various solid tumors.Vergent Bioscience generates revenue through partnerships with healthcare providers, focusing on hospitals and surgical clinics. Revenue is primarily derived from the sale of VGT-309 for surgical procedures, structured through direct sales agreements reflecting the product's clinical value and operational costs. The company aims to expand into new markets and regions, although specific targets have not been disclosed.
Who invested in Vergent Bioscience
7 investors across 2 rounds
See all investors in Vergent Bioscience
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Vergent Bioscience
Who invested in Vergent Bioscience?
Vergent Bioscience has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Vergent Bioscience raised?
Vergent Bioscience has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Vergent Bioscience last raise money?
Vergent Bioscience's most recent round on record is a Series B, in Aug 2022.
What does Vergent Bioscience do?
Vergent Bioscience develops advanced tumor-targeted fluorescent imaging agents, enhancing tumor visibility during surgeries.
Where is Vergent Bioscience headquartered?
Vergent Bioscience is headquartered in Minneapolis, US.
Which VCs invest in companies like Vergent Bioscience?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Vergent Bioscience's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Vergent Bioscience? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.